⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068500 | 0.64 | — | — | |
| SCHEMBL4947130 | 0.62 | — | — | |
| SCHEMBL19629434 | 0.57 | — | — | |
| SCHEMBL18323892 | 0.57 | — | — | |
| SCHEMBL2498167 | 0.53 | OR51E2 (0.31) | — | |
| SCHEMBL9875700 | 0.47 | — | — | |
| SCHEMBL9856988 | 0.45 | — | — | |
| SCHEMBL22296920 | 0.45 | — | — | |
| SCHEMBL14375260 | 0.37 | — | — | |
| SCHEMBL8493529 | 0.30 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210378964-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC | 2021-12-09 | — | — | US | disclosed |
| US-20200030239-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC (F/K/A VIVUS, INC.) | 2020-01-30 | — | — | US | disclosed |
| US-20190133955-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10028916-B2 | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use | VIVUS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160331687-A1 | ORALLY DISINTEGRATING DOSAGE FORM FOR ADMINISTRATION OF AVANAFIL, AND ASSOCIATED METHODS OF MANUFACTURE AND USE | VIVUS LLC (F/K/A VIVUS, INC.) | 2016-11-17 | — | — | US | disclosed |
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-6797709-B2 | SEXUAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |